Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effectiveness of Self-posturotherapy on the Elimination of Residual Fragments After Treatment of Lower Calyx Urinary Stones by Extracorporeal Lithotripsy or Retrograde Flexible Ureteroscopy.

NCT06793540 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-06-30
Last updated
2025-07-08

Condition(s) studied

Stone, Kidney

Investigational drug(s) / intervention(s)

SELF POSTUROTHERAPIE

SELF POSTUROTHERAPIE: a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.

Study summary

The main objective of this study is to evaluate the effectiveness of an auto posturotherapy technique on the RFS at three months of patients treated for lower calyceal urinary stones by extracorporeal lithotripsy (ECL) or retrograde flexible ureteroscopy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
pré Inclusion Criteria: * Patient having read and signed the consent form for participation in the study • Patient candidate for an intervention on a lower calyx stone \<15mm by LEC or URSS Patients meeting all of the following criteria may be definitively included in the study: * Patient treated by LEC, or patient treated by URSS and for whom the presence of lower calyceal fragments has been observed by endoscopy * Absence of JJ stent (patients for whom a JJ stent was implanted after URSS or before LEC may be included as soon as it is removed) Exclusion Criteria: * Patients presenting one of the following criteria will not be included in the study: * Renal or ureteral malformation: ureteral stenosis, pyelo-ureteral junction syndrome, horseshoe kidney, para calyceal diverticulum, pelvic kidney. * LEC session interrupted due to treatment intolerance * Physical disability making posturotherapy impossible (particularly spinal, etc.), morbid obesity, major gastroesophageal reflux, heart or respiratory failure. * Balance disorder which would not allow self-posturotherapy to be carried out alone. * Patient under legal protection, under guardianship or under curatorship * Posturotherapy carried out while wearing a JJ probe * Posturotherapy carried out by a third party (physiotherapist or other) * Pregnant or breastfeeding patient * Patient not affiliated to the French social security system * Impossibility of providing the subject with informed information and/or giving written informed consent: dementia, psychosis, disorders of consciousness, non-French speaking patient * Treatment that may modify the clearance of fragments (beta blocker, diuretic, etc.) * Patient included in another therapeutic study protocol

Primary outcome measure(s)

  • stone free rate — 3 month

Trial sites (2)

FacilityCityRegionStatus
Hôpital Edouard Herriot - Lyon France Recruiting
Clinique La Croix du Sud Quint-Fonsegrives France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06793540 on ClinicalTrials.gov ↗ ← All trials in France